ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

India's Biocon Biologics to receive $150m from Goldman Sachs

Fresh infusion follows Tata's pledge of $30m

Employees of parent Biocon work inside the company's research and development facility in Bangalore, India.   © Reuters

NEW DELHI -- Biocon Biologics, a subsidiary of Indian biotech giant Biocon, has secured board approval for an investment of $150 million from U.S.-based investment bank Goldman Sachs.

As part of the agreement, Goldman Sachs will be issued convertible debentures at a post-money equity valuation of $3.94 billion, the parent said in a statement.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more